Globe Newswire07.18.18
Nu-Med Plus Inc., a medical device company that explores and develops applications of new healthcare technologies, has filed for a patent covering its chemically reactive coating. The coating ensures that only a contaminant free nitric oxide—a life saving drug for neonates—reaches the patient.
Nu-Med Plus has developed a distinctive method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing. The coating essentially removes toxic contaminants that are found in nitric oxide delivery systems. The technique was developed to augment Nu-Med’s capability to deliver high purity Inhaled Nitric Oxide(INO) to the patient at point of use. A patent has been applied for protecting this advancement.
Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), chronic obstructive pulmonary disease, and other pulmonary problems and may have future applications for a variety of global diseases and complications that are currently being investigated.
“The Nu-Med Plus goal is to increase its intellectual property portfolio by developing exceptional methods for the distribution of Inhaled Nitric Oxide (INO) and to safeguard its low cost INO technology which will enable us to add value to the company and increases our competitive advantage," commented Jeff Robins, president and CEO of Nu-Med Plus.
Nu-Med Plus Inc. is focused on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use.
Nu-Med Plus has developed a distinctive method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing. The coating essentially removes toxic contaminants that are found in nitric oxide delivery systems. The technique was developed to augment Nu-Med’s capability to deliver high purity Inhaled Nitric Oxide(INO) to the patient at point of use. A patent has been applied for protecting this advancement.
Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), chronic obstructive pulmonary disease, and other pulmonary problems and may have future applications for a variety of global diseases and complications that are currently being investigated.
“The Nu-Med Plus goal is to increase its intellectual property portfolio by developing exceptional methods for the distribution of Inhaled Nitric Oxide (INO) and to safeguard its low cost INO technology which will enable us to add value to the company and increases our competitive advantage," commented Jeff Robins, president and CEO of Nu-Med Plus.
Nu-Med Plus Inc. is focused on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use.